About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Prostate Cancer Clinical Trials in Ohio | 525 Studies

Clinical Trials Prostate CancerOhio

Prostate Cancer Clinical Trials in Ohio

Find 525 clinical trials for prostate cancer near Ohio. Connect with research centers in your area.

All Prostate Cancer trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 161-180 of 525 trials

CompletedFor Cause Prostate Biopsy in REDUCE Population TrialThe REDUCE trial was conducted to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the…NCT01529086·Cleveland, Ohio RecruitingHugo™ Robotic Assisted Surgery (RAS) System in Prostatectomy Patients Treated in an ASC SettingA Single-center Study of Robotic Prostatectomy Surgeries Performed using the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in an Ambulatory Surgical Center SettingNCT07875192·Columbus, Ohio CompletedA Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerThe primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancerNCT00055471·Cleveland, Ohio and 1 other

Prostate Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedPROvenge Treatment and Early Cancer TreatmentThe PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer.NCT00779402·Berkeley, California and 17 others

TerminatedPhase II, Dose Finding Study of GTx-758The purpose of this study is to determine the appropriate loading and maintenance dose of GTx-758 to reach and maintain castration for the duration of the study.NCT01393119·Glendale, Arizona and 20 others

Active not recruitingA Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCThe purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC)…NCT05884398·Homewood, Alabama and 92 others

TerminatedJavelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsAvelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung…NCT03330405·Fayetteville, Arkansas and 65 others

RecruitingDocetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseThis study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs?NCT06592924·Anchorage, Alaska and 394 others

CompletedTrial of ARV-110 and Abiraterone in Participants With Metastatic Prostate CancerPhase 1b study to assess the combination of ARV-110 (bavdegalutamide) and abiraterone in participants with metastatic prostate cancer with rising PSA values on abiraterone.NCT05177042·Santa Monica, California and 17 others

RecruitingA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC).NCT06925737·Phoenix, Arizona and 302 others

RecruitingProstate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world.NCT06705803·Hyde Park, Illinois and 1 other

CompletedDarolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerThe purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel…NCT02799602·Chandler, Arizona and 321 others

Active not recruitingMedtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.NCT05696444·Duarte, California and 5 others

CompletedPivotal Study of the NanoKnife System for the Ablation of Prostate TissuePivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients.NCT04972097·Orange, California and 16 others

CompletedObservational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.NCT02380274·Homewood, Alabama and 147 others

CompletedObservational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate CancerObservational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer…NCT02141438·Anchorage, Alaska and 67 others

RecruitingFK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate CancerThe goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate…NCT06636682·Chicago, Illinois and 2 others

CompletedLenalidomide and GM-CSF in Treating Patients With Prostate CancerRATIONALE: Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.NCT00939510·Cleveland, Ohio

Active not recruitingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersTTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy…NCT04485013·Tucson, Arizona and 40 others

RecruitingStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy…NCT05519449·Birmingham, Alabama and 37 others

PreviousPage 9 of 27Next

Other Conditions in Ohio

Breast Cancer Lung Cancer Colorectal Cancer Melanoma Leukemia Lymphoma